Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, July 14, 2015, 28 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $43.20 to $1,115,800.00.

Highlighted Stocks Traded by Insiders:

Valhi (VHI) - FREE Research Report

Mcilroy W Hayden, who is Director at Valhi, bought 1,000 shares at $4.88 on July 14, 2015. Following this transaction, the Director owned 26,500 shares meaning that the stake was boosted by 3.92% with the 1,000-share transaction.

The shares most recently traded at $4.86, down $0.02, or 0.41% since the insider transaction. Historical insider transactions for Valhi go as follows:

  • 4-Week # shares bought: 33,150
  • 4-Week # shares sold: 300,000
  • 12-Week # shares bought: 33,150
  • 12-Week # shares sold: 300,000
  • 24-Week # shares bought: 33,150
  • 24-Week # shares sold: 300,000

The average volume for Valhi has been 87,400 shares per day over the past 30 days. Valhi has a market cap of $1.6 billion and is part of the basic materials sector and chemicals industry. Shares are down 26.21% year-to-date as of the close of trading on Tuesday.

Valhi, Inc., through its subsidiaries, engages in the chemicals, component products, waste management, and real estate businesses worldwide. The stock currently has a dividend yield of 1.66%. The company has a P/E ratio of 24.1. Currently, there are no analysts who rate Valhi a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VHI - FREE

TheStreet Quant Ratings rates Valhi as a hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income and notable return on equity. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow, a generally disappointing performance in the stock itself and generally higher debt management risk. Get the full Valhi Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Synnex (SNX) - FREE Research Report

Larocque Peter, who is President, N.A. Distribution at Synnex, sold 12,500 shares at $73.29 on July 14, 2015. Following this transaction, the President, N.A. Distribution owned 17,293 shares meaning that the stake was reduced by 41.96% with the 12,500-share transaction.

The shares most recently traded at $73.59, up $0.30, or 0.41% since the insider transaction. Historical insider transactions for Synnex go as follows:

  • 4-Week # shares sold: 400
  • 12-Week # shares sold: 1,200
  • 24-Week # shares sold: 19,692

The average volume for Synnex has been 213,800 shares per day over the past 30 days. Synnex has a market cap of $2.9 billion and is part of the services sector and diversified services industry. Shares are down 5.64% year-to-date as of the close of trading on Tuesday.

SYNNEX Corporation provides business process services to resellers, retailers, and original equipment manufacturers in the United States, Japan, and internationally. It operates in two segments, Technology Solutions and Concentrix. The stock currently has a dividend yield of 0.68%. The company has a P/E ratio of 14.5. Currently, there are 2 analysts who rate Synnex a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SNX - FREE

TheStreet Quant Ratings rates Synnex as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and notable return on equity. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Synnex Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Supernus Pharmaceuticals (SUPN) - FREE Research Report

Schwabe Stefan K.F., who is Executive Vice President R&D at Supernus Pharmaceuticals, sold 1,950 shares at $19.23 on July 14, 2015. Following this transaction, the Executive Vice President R&D owned 844 shares meaning that the stake was reduced by 69.79% with the 1,950-share transaction.

The shares most recently traded at $19.48, up $0.25, or 1.28% since the insider transaction. Historical insider transactions for Supernus Pharmaceuticals go as follows:

  • 4-Week # shares sold: 2,051
  • 12-Week # shares sold: 5,682
  • 24-Week # shares sold: 5,682

The average volume for Supernus Pharmaceuticals has been 1.1 million shares per day over the past 30 days. Supernus Pharmaceuticals has a market cap of $903.7 million and is part of the health care sector and drugs industry. Shares are up 130.36% year-to-date as of the close of trading on Tuesday.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company has a P/E ratio of 26.3. Currently, there are 5 analysts who rate Supernus Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SUPN - FREE

TheStreet Quant Ratings rates Supernus Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Supernus Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.